Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (541)	6/27/2001 10:27:51 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Competitor, Soluble IL-4 Receptor Effective in Asthma Treatment -------------------------------------------------------------------------------- WESTPORT, CT (Reuters Health) Jun 26 - Among patients with moderate persistent asthma, a soluble interleukin-4 receptor (IL-4R), which acts as an IL-4 antagonist, appears to be safe and effective in preventing a decline in lung function and in preventing asthma symptoms. Dr. Larry C. Borish, from the University of Virginia Health Sciences Center in Charlottesville, and colleagues randomized 62 subjects with moderate persistent asthma to IL-4R or placebo. Before the subjects were randomized they were taken off inhaled corticosteroids, according to the research team's report in the June issue of the Journal of Allergy and Clinical Immunology. During the 12 weeks of the trial, those in the IL-4R group received weekly doses of 0.75 mg, 1.5 mg, or 3.0 mg of IL-4R. Among patients receiving the 3.0-mg dose, there was no decline in FEV1; however, lung function did decline among those receiving placebo. In addition there was no increase in asthma symptoms among those receiving 3.0 mg of IL-4R, Dr. Borish's team reports. This study is "the first...to demonstrate the potential clinical efficacy of a TH2 inhibitor for the treatment of asthma," the investigators note. "An anti-inflammatory agent that is not a corticosteroid and that selectively inhibits allergic mechanisms will be a significant advance in the treatment of asthma....These data demonstrate the critical role of IL-4 in the pathogenesis of asthma and the potential benefit of this approach to therapy," Dr. Borish and colleagues conclude. J Allergy Clin Immunol 2001;107:963-970.

To: Miljenko Zuanic who wrote (541)	7/5/2001 11:09:33 PM
From: Scott H. Davis	Respond to of 3557

Miljenko & All: now that it has been a couple weeks since you posted about the lack of folks making calls about oversold/entry & overbougt/profit take points, I thought I'd point out some cases in this interval I called. Not to say "yeah me" but to show what you can do when you combine somehttp://www.siliconinvestor.com/research/chart.gsp?lotemp=&period=120&chart1=bb&s=ptix&compare=&time=day&i0=2&chart=bar&i1=3&scale=linear&i2=9&i3=8 simple, free TA tools (right on SI) WITH following the stocks involved for a long time on a fundimental & business case basis. I said on 6/8 that Regeneron was overbought and onlikely to jump from the mid 30s to 45+ (the option vulnerability point) by 8/3. I also asked about the prospect of material good news in that timespan (again, fusing both the business case and the TA) Here's how it looked at the time siliconinvestor.com I don't look at just 1 indicator, as they give a lot of false signals. So here's 4. RSI > 70 is overbought, the higher, the more so. I tend to use 75 for safety. Stockastics > 75 is also overbought (I use 80). As these go 1-100, reverse that & you have oversold. Bollinger bands - high or low, look for prices at or above the upper line for overbouht. No when a stock is on an oversold or overbought basis, it can stay there for several days, sometimes weeks on a hot stock (not too often.) Williams %r is an indicator of a stocks liklieness to retrace. Much more vollitle. With DMI, you rately see the green line above or below both the blue and red lines for long. Note that since 6/8, it's underperformed the NAZ. In contrast, on 6/19, I put in buys for ADIC (digital storage) and PTIX (networking) on 6/19 as they were both really oversold. I also have held these stock for most of the last couple years (stepped asside for a while when the NAZ went bonkers winter 2000 then rebought cheaper later) I was confident based on my ongoing DD that there was no adverse fundimental news. I put in limit buys. Did not hit it perfectly. I bought PTIX at 11.8 (had been at 16 recently before that) it actually continued down to 10. I put in a limit buy for ADIC at 15.20 when it was just under 16. Got a little too greedy. 15.30 would have bought. I posted on the ADIC thread that ADIC was oversold & that I was buying the before the open on 6/20. The PTIX thread is dead so I did not bother, but I have the trade confirm. But they both have respectible rebound gains, and represent a good long term hold from the point I bought and neerly bought. Here's the chart. About the inverse of REGN. ADIC post with the chart link Message 15968602 Here's the similar PTIX chart siliconinvestor.com I really think biotech investors that follow companies well arleady fundimantally can see additional gains by adding some TA to their bag of tools. IMSCO Scott

To: Miljenko Zuanic who wrote (541)	7/6/2001 8:48:44 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 3557

MZ, REGN is now approaching oversold territory. Not serious yet, and the market sentiment is still down. May well sink more. A good till filled limit buy iin the 28-29 range has a good chance of being filled. As an example of what I referred to before as accumulation trading in a company you want to have an increasing long term long position in, using oversold and overbought really can help. Selling a position at 37 when overbought and re-buying at 29 when oversold yields 20% more shares for the portion you traded. Please forgive if I come across as preaching. You and others with a strong science background contribute so much to these threads. This is a way I can give back some insights, hopefully in a constructive format. But enough on this unless there are any questions. Scott